Progyny (NASDAQ:PGNY - Get Free Report) has been given a $27.00 price target by equities researchers at Truist Financial in a research report issued on Thursday, Marketbeat reports. The firm currently has a "hold" rating on the stock. Truist Financial's price objective would suggest a potential upside of 17.34% from the company's current price.
Other equities analysts have also recently issued research reports about the stock. Leerink Partnrs upgraded shares of Progyny from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 8th. Canaccord Genuity Group dropped their price objective on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a research note on Monday, March 31st. Finally, Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 target price for the company in a report on Tuesday, July 8th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $24.82.
Read Our Latest Stock Report on PGNY
Progyny Price Performance
Shares of Progyny stock traded down $0.01 on Thursday, reaching $23.01. 1,106,815 shares of the company traded hands, compared to its average volume of 1,717,425. Progyny has a 52 week low of $13.39 and a 52 week high of $29.78. The company has a 50 day moving average of $21.79 and a 200 day moving average of $21.73. The firm has a market capitalization of $1.97 billion, a PE ratio of 40.37, a PEG ratio of 2.37 and a beta of 1.31.
Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 10.90% and a net margin of 4.33%. The business had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same period last year, the business posted $0.17 earnings per share. The firm's quarterly revenue was up 16.5% on a year-over-year basis. As a group, analysts anticipate that Progyny will post 0.6 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Cheryl Scott sold 2,675 shares of Progyny stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total value of $59,037.25. Following the completion of the sale, the director directly owned 14,112 shares in the company, valued at $311,451.84. This trade represents a 15.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.40% of the stock is owned by company insiders.
Institutional Investors Weigh In On Progyny
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New York State Teachers Retirement System increased its stake in shares of Progyny by 0.7% during the first quarter. New York State Teachers Retirement System now owns 73,200 shares of the company's stock worth $1,635,000 after buying an additional 500 shares during the period. Leibman Financial Services Inc. increased its stake in Progyny by 1.1% in the second quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company's stock valued at $1,011,000 after purchasing an additional 513 shares during the last quarter. Voya Investment Management LLC increased its stake in Progyny by 1.4% in the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock valued at $893,000 after purchasing an additional 701 shares during the last quarter. Polen Capital Management LLC boosted its holdings in shares of Progyny by 0.3% in the first quarter. Polen Capital Management LLC now owns 261,506 shares of the company's stock valued at $5,842,000 after acquiring an additional 798 shares during the period. Finally, Militia Capital Partners LP boosted its holdings in shares of Progyny by 100.0% in the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after acquiring an additional 1,000 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.
Progyny Company Profile
(
Get Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
